arrow
A

Akihiko Miyanaga

saitama cancer center
H指数:19
被引数:1,488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase I and early phase II study of enhancing immune checkpoint inhibitor efficacy using a Mycobacterium tuberculosis extract combined with radiation therapy in non-small cell lung cancer patients: NEJ046A

I期和早期II期研究:在非小细胞肺癌患者中使用结核分枝杆菌提取物联合放射疗法增强免疫检查点抑制剂疗效:NEJ046A

2026-10-180
PRE
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B Study

一项关于阿法替尼与培美曲塞和卡铂联合治疗EGFR突变阳性、非鳞状、晚期非小细胞肺癌(NSCLC)患者(对一线奥希替尼治疗耐药)的II期研究:NEJ025B研究

2025-08-200
PRE
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素:NINJA研究的亚组分析

2025-03-150
OA
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响:NINJA研究的亚组分析

2025-02-140
OA
Retrospective study on the tolerability of anti-PD-L1 antibody plus platinum-etoposide for elderly patients with extensive- stage small-cell lung cancer based on body mass index

基于体质量指数的回顾性研究:PD-L1抗体联合铂类-依托泊苷在广泛期小细胞肺癌老年患者中的耐受性

2024-12-010
PRE
IgA vasculitis induced by carboplatin plus nab-paclitaxel plus pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report
2024-08-140
OAAI
Phosphoproteomic Analysis Identi fied Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

磷酸化蛋白质组学分析证实FAK和Src的相互磷酸化是EGFR突变肺癌中奥希替尼耐药的机制

2024-04-012
OA
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
2023-12-014
OA
Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC

铂类双重化疗联合免疫检查点抑制剂治疗晚期非鳞状NSCLC患者TTF-1表达弥漫性阳性的预测作用

2023-11-011
OA
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

晚期非小细胞肺癌中基于铂类化疗联合程序性死亡-1阻滞后ramucirumab联合多西他赛的多中心真实数据: NEJ051 (反应性研究)

2023-05-0110
PRE